Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast Cancer

Chau Dang, MD
Published: Tuesday, Jul 26, 2016



Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.

The study, which was originally reported by Hope Rugo, MD, at the 2016 ASCO Annual Meeting, looked at the activity of MYL-1401O with a taxane versus trastuzumab (Herceptin) with a taxane in the first-line setting of patients with HER2-positive metastatic breast cancer. This equivalency trial showed that the proposed biosimilar MYL-1401O was equivalent to trastuzumab in terms of efficacy and safety.

Because trastuzumab is not available worldwide due to cost factors, this biosimilar data could eventually lead to more affordable, global options for patients.


Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.

The study, which was originally reported by Hope Rugo, MD, at the 2016 ASCO Annual Meeting, looked at the activity of MYL-1401O with a taxane versus trastuzumab (Herceptin) with a taxane in the first-line setting of patients with HER2-positive metastatic breast cancer. This equivalency trial showed that the proposed biosimilar MYL-1401O was equivalent to trastuzumab in terms of efficacy and safety.

Because trastuzumab is not available worldwide due to cost factors, this biosimilar data could eventually lead to more affordable, global options for patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Publication Bottom Border
Border Publication
x